Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937664 | 0.93 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938989 | 0.91 | HDAC3 (0.87) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938042 | 0.89 | HDAC3 (0.80) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938429 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938335 | 0.88 | HDAC3 (0.78) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938025 | 0.87 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938823 | 0.87 | HDAC3 (0.77) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1937940 | 0.85 | HDAC3 (0.74) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL2631173 | 0.85 | HDAC3 (0.76) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL529065 | 0.84 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112135610-A | Combination of a selective histone deacetylase 3(HDAC3) inhibitor and an immunotherapeutic for the treatment of cancer | KDAc治疗股份有限公司 | 2020-12-25 | — | — | CN | claimed |
| EP-3737362-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAC THERAPEUTICS, INC. (US) | 2020-11-18 | — | — | EP | claimed |
| US-9796664-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-10-24 | — | — | US | claimed |
| EP-2330894-B1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORP (US) | 2016-12-21 | — | — | EP | claimed |
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION | 2016-05-05 | — | — | US | claimed |
| US-9265734-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-02-23 | — | — | US | claimed |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | REPLIGEN CORPORATION (US) | 2012-04-19 | — | — | US | claimed |
| EP-2330894-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010028192-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | claimed |
| US-20250255839-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAc Therapeutics, Inc. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12128018-B2 | Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer | KDAc Therapeutics, Inc. (US) | 2024-10-29 | — | — | US | disclosed |
| US-11377423-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAc Therapeutics, Inc. | 2021-06-17 | — | — | US | disclosed |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAc Therapeutics, Inc. | 2021-06-17 | — | — | US | disclosed |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | REPLIGEN CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | REPLIGEN CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012016081-A2 | METHOD AND THERAPEUTIC FOR THE TREATMENT AND REGULATION OF MEMORY FORMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-2330894-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010028192-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028192-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | HDAC3 1/4885HDAC1 2/4885NCOR2 130/4885 |
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | HDAC1, HDAC5, HDAC2 | HDAC3 5/4885HDAC1 1/4885NCOR2 55/4885 |
| US-20250255839-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885HDAC1 2/4885NCOR2 76/4885 |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | HDAC1, HDAC5, HDAC2 | HDAC3 5/4885HDAC1 1/4885NCOR2 55/4885 |
| US-12128018-B2 | Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885HDAC1 2/4885NCOR2 76/4885 |
| US-11377423-B2 | Inhibitors of histone deacetylase | HDAC3, HDAC1, HDAC11 | HDAC3 1/4885HDAC1 2/4885NCOR2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.